Health Economics›Malignant pleural mesothelioma›Advanced or metastatic disease first-line therapy

Advanced or metastatic disease first-line therapy

Malignant pleural mesothelioma · 14 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 2 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Carboplatin, Pemetrexed, Pembrolizumab Variant #01	—	R 83 725	21d	—	17.3 mo	—	—	1
Cisplatin, Pemetrexed, Pembrolizumab Variant #01	—	R 83 075	21d	—	17.3 mo	—	—	1
Ipilimumab and Nivolumab Variant #01 Partial	—	R 78 615	42d	—	18.1 mo	—	—	1
Cisplatin, Pemetrexed, Bevacizumab Variant #01	—	R 29 711	21d	—	18.8 mo	—	—	1
Carboplatin, Pemetrexed, Bevacizumab Variant #01	—	R 16 050	21d	—	18.1 mo	—	—	1
Cisplatin and Gemcitabine (GC) Variant #34	—	R 15 338	56d	~6.9 mo	~11.9 mo	~4	~R 61 352 PFS proxy · indirect	59
Cisplatin and Pemetrexed Variant #01	—	R 1 088	21d	7.0 mo	16.1 mo	11	R 11 964 PFS proxy	5
Cisplatin, Pemetrexed, TTFields Variant #01	—	R 1 088	21d	—	—	—	—	—
Cisplatin monotherapy Variant #16	—	R 650	28d	—	9.1 mo	—	—	2
Vinorelbine monotherapy Variant #01	—	R 583	21d	—	9.5 mo	—	—	1
Cisplatin and Raltitrexed Variant #01 Partial	—	R 400	21d	—	11.4 mo	—	—	1
Pemetrexed monotherapy N/A - secondary systemic drug	—	R 69	21d	—	~9.7 mo	—	—	—
Carboplatin and Pemetrexed N/A - secondary systemic drug	—	R 52	21d	—	15.1 mo	—	—	2
Best supportive care Partial	—	—	—	—	~12.8 mo	—	—	2

14 of 14 regimens shown